Hypericin PDT more effective than placebo after six weeks of treatment; index lesion response rate increased with progressive cycles of treatment

No over-the-counter medications have FDA approval for the removal of moles and skin tags

Dose-response relationship seen, with greater risk with more severe eczema

Asian patients have visits of shorter mean duration compared with White patients, non-Asian patients as a single group

75 percent improvement in Eczema Area and Severity Index was 82.5 percent with two years of tralokinumab

No significant differences seen in mean primary melanoma Breslow thickness for prepandemic era, subsequent periods

Company says it has not received any reports of adverse events

Response rates for deucravacitinib significantly higher versus placebo or apremilast for PASI 75, sPGA 0/1

Response rates for deucravacitinib significantly higher versus placebo or apremilast for PASI 75, sPGA 0/1

Readers most accurately discriminated between thin (≤1.0 mm) and thick melanomas (>1.0 mm)

95 percent of 528 cases presented with rash; 73 and 41 percent had anogenital and mucosal lesions, respectively

Three types of infiltrates revealed on histologic examination including cutaneous T-cell lymphoid hyperplasia

No association seen with risk for local recurrence, but five-year disease-specific mortality lower for patients with clear margins versus close/involved margins

Opzelura can be used twice daily in patients ages 12 years and older

Causal effect found of smoking initiation, cigarettes per day, lifetime smoking on psoriasis; no causal link seen for alcohol consumption

Those with concomitant atopic dermatitis, asthma had increased risk for hospitalizations and fewer visits in outpatient clinics

Odds of complete clearance of MC lesions increased for patients receiving berdazimer gel 10.3 percent versus vehicle for 12 weeks

Adjusted survival curves from the multivariable model for effectiveness showed higher drug survival for guselkumab

Complete disease clearance observed in 41 percent of patients with tapinarof cream 1 percent used once daily

Survey shows lack of knowledge may lead to behaviors that contribute to sun damage, skin cancer

Adjusted survival curves from the multivariable model for effectiveness showed higher drug survival for guselkumab

Based on validated IGA, EASI, POEM, and CDLQI, the Skindex-Mini Total score could distinguish atopic dermatitis severity